Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTransplantation ChimeraTreatment OutcomeStem CellsGraft SurvivalGraft vs Leukemia EffectBone Marrow TransplantationMyeloablative AgonistsTissue DonorsBusulfanRemission InductionRecurrenceVidarabineGraft vs Tumor EffectHistocompatibility TestingRetrospective StudiesLymphocyte TransfusionImmunosuppressive AgentsLeukemia, Myeloid, AcuteMultiple MyelomaLeukemiaCombined Modality TherapySiblingsCord Blood Stem Cell TransplantationLiver TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCytomegalovirus InfectionsHematopoietic Stem CellsMinor Histocompatibility AntigensSurvival AnalysisSalvage TherapyWhole-Body IrradiationSurvival RateDisease-Free SurvivalLymphocyte DepletionAntilymphocyte SerumMyelodysplastic SyndromesVirus ActivationNeoplasm, ResidualHistocompatibilityPrecursor Cell Lymphoblastic Leukemia-LymphomaTime FactorsMelphalanChimerismHepatic Veno-Occlusive DiseaseFollow-Up StudiesMesenchymal Stem Cell TransplantationKidney TransplantationCyclophosphamideAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusHematopoietic Stem Cell MobilizationT-LymphocytesAcute DiseasePrognosisCell TransplantationPrimary MyelofibrosisAnemia, AplasticHLA AntigensEmbryonic Stem CellsHematologic DiseasesLeukemia, Myeloid, Accelerated PhaseTransplantation ImmunologyAntigens, CD34ImmunosuppressionAntibodies, NeoplasmRoseolovirus InfectionsCytarabineBenzamidesAdult Stem CellsImmunocompromised HostLymphoproliferative DisordersAntineoplastic AgentsLeukemia, MyeloidFusion Proteins, bcr-ablReceptors, Purinergic P2X5Hodgkin DiseasePyrimidinesProspective StudiesNuclear FamilyGraft RejectionHeart TransplantationCyclosporineFatal OutcomeInfectionLiving DonorsGanciclovirGranulocyte Colony-Stimulating FactorLymphoma, Non-HodgkinPiperazinesRisk FactorsImmunotherapy, AdoptiveTransplantation, Isogeneic